We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
35.00 | 1.82% | 1,960.00 | 1,970.00 | 1,972.00 | 1,977.00 | 1,931.00 | 1,937.00 | 318,030 | 16:35:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 22.68 | 4.36B |
TIDMHIK
RNS Number : 1308R
Hikma Pharmaceuticals Plc
25 June 2020
TR-1: S tandard form for notification of major holdings
LONDON, 25 June 2020 - Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) (LSE: HIK) announces as follows:
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) (i) 1a. Identity of the issuer or the Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) underlying issuer of existing shares to which voting rights are attached (ii) : -------------------------------------------------------- 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer ---- 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights X ---- An acquisition or disposal of financial instruments ---- An event changing the breakdown of voting rights ---- Other (please specify)(iii) : ---- 3. Details of person subject to the notification obligation (iv) Name Boehringer Ingelheim Invest GmbH City and country of registered office Ingelheim am Rhein, Germany (if applicable) 4. Full name of shareholder(s) (if different from 3.) (v) Name N/A -------------------------------------------------------- City and country of registered office N/A (if applicable) -------------------------------------------------------- 5. Date on which the threshold was 23 June 2020 crossed or reached (vi) : 25 June 2020 -------------------------------------------------------- 6. Date on which issuer notified (DD/MM/YYYY): 25 June 2020 -------------------------------------------------------- 7. Total positions of person(s) subject to the notification obligation % of voting % of voting rights Total of both Total number rights attached through financial in % (8.A + of voting rights to shares (total instruments 8.B) of issuer (vii) of 8. A) (total of 8.B 1 + 8.B 2) --------------------- ----------------------- -------------------- ------------------------ Resulting situation 23 June 2020: 0 23 June 2020: 23 June 2020: on the date 12,833,233 shares 12,833,233 shares 12,833,233 on which threshold bought back bought back shares bought was crossed by the issuer by the issuer back by the or reached with a resultant with a resultant issuer with position of position of a resultant 11.16%. 11.16%. position of 25 June 2020: 25 June 2020: 27,166,767. Remaining 27,166,767 Remaining 25 June 2020: shares sold 27,166,767 Remaining 27,166,767 in a placing shares sold shares sold with a resultant in a placing in a placing position of with a resultant with a resultant 0%. position of position of 0%. 0. --------------------- ----------------------- -------------------- ------------------------ Position of previous notification (if applicable) 16.67% 0 16.67% --------------------- ----------------------- -------------------- ------------------------ 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached (viii) A: Voting rights attached to shares Class/type of Number of voting rights % of voting rights shares (ix) ISIN code (if possible) Direct Indirect Direct Indirect (Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive 2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC) (DTR5.1) (DTR5.2.1) (DTR5.2.1) -------------------------- 23 June 2020: 12,833,233 shares bought back 23 June 2020: by the issuer 12,833,233 shares with a resultant bought back by position of the issuer with 27,166,767 . a resultant position 25 June 2020: of 11.16%. Remaining 27,166,767 25 June 2020: shares sold Remaining 27,166,767 in a placing shares sold in Ordinary shares with a resultant a placing with of 10 pence each position of a resultant position (GB00B0LCW083) 0. 0 of 0%. 0 ------------------------ -------------------------- ------------------------- --------------------- SUBTOTAL 8. A 23 June 2020: 27,166,767 23 June 2020: 11.16% 25 June 2020: 0 25 June 2020: 0% ---------------------------------------------------- ------------------------------------------------ B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Type of financial Expiration Exercise/ Number of voting % of voting instrument date Conversion Period rights that may rights (x) (xi) be acquired if the instrument is exercised/converted. ------------ ------------------------------- -------------------------------- --------------------- N/A -------------------------------------------- -------------------------------- --------------------- SUBTOTAL 8. B 1 -------------------------------------------- -------------------------------- --------------------- B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) Type of Expiration Exercise/ Physical or Number of % of voting financial date (x) Conversion cash voting rights rights instrument Period (xi) settlement (xii) ------------------ --------------------- -------------------- -------------------- N/A
--------- -------------------- -------------------- SUBTOTAL 8.B.2 -------------------- -------------------- 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (xiii) Full chain of controlled undertakings through which the voting rights X and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (xiv) (please add additional rows as necessary) Name (xv) % of voting rights % of voting rights Total of both if if it equals or through financial it equals or is is higher than the instruments if it higher than the notifiable threshold equals or is higher notifiable threshold than the notifiable threshold ---------------------- --------------------- ------------------------ C.H. Boehringer Sohn AG & Co. KG 0 0 0 ---------------------- --------------------- ------------------------ Boehringer Ingelheim Corporate Center GmbH 0 0 0 ---------------------- --------------------- ------------------------ Boehringer Ingelheim Verwaltungs GmbH 0 0 0 ---------------------- --------------------- ------------------------ Boehringer Ingelheim International GmbH 0 0 0 ---------------------- --------------------- ------------------------ Boehringer Ingelheim Auslandsbeteiligungs GmbH 0 0 0 ---------------------- --------------------- ------------------------ 10. In case of proxy voting, please identify: Name of the proxy holder N/A ----------------------------------------------- The number and % of voting rights N/A held ----------------------------------------------- The date until which the voting rights N/A will be held ----------------------------------------------- 11. Additional information (xvi) None Place of completion Germany Date of completion Buyback by the issuer completed 23 June 2020. Sale in the placing completed 25 June 2020. ----------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
HOLUVAVRRRUNUAR
(END) Dow Jones Newswires
June 25, 2020 11:12 ET (15:12 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions